IMMUNE-MEDIATED MYASTHENIA GRAVIS

This adverse event was reported 325 times

These drugs are most commonly taken by patients reporting IMMUNE-MEDIATED MYASTHENIA GRAVIS:

# Drug Count
0 PEMBROLIZUMAB 153
1 NIVOLUMAB 121
2 IPILIMUMAB 57
3 CARBOPLATIN 20
4 DURVALUMAB 19
5 LENVATINIB 18
6 PACLITAXEL 12
7 PACLITAXEL (AIBUMIN-BOUND) 12
8 CISPLATIN 11
9 OXALIPLATIN 10
See all common drugs associated with IMMUNE-MEDIATED MYASTHENIA GRAVIS

IMMUNE-MEDIATED MYASTHENIA GRAVIS is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 FENBENDAZOLE 1 0.0093
1 NIVOLUMAB AND RELATLIMAB-RMBW 3 0.0058
2 PEMBROLIZUMAB 153 0.0014
3 TREMELIMUMAB 6 0.0014
4 POTASSIUM IODIDE 2 0.0013
5 IPILIMUMAB 57 0.0013
6 NIVOLUMAB 121 0.0012
7 ENFORTUMAB VEDOTIN 8 0.0010
8 DURVALUMAB 19 0.0009
9 VONOPRAZAN FUMARATE 6 0.0007
See all drugs enriched for association with IMMUNE-MEDIATED MYASTHENIA GRAVIS